KRAS and colonic neoplasm: Metastatic colon cancers are routinely tested for mutant KRAS to determine suitability for biologic adjuvant therapy with the anti-epidermal growth factor receptor (EGFR) antibody, cetuximab [37], as surprisingly, patients with mutant KRAS fared worse with anti-EGFR therapy than without treatment [37].